ArticlemSystems2024
Adaptive attenuation of virulence in hypervirulent carbapenem-resistant
Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of hypervirulentFrontiers in medicine · 2025Pooled it
- Post-infection colonization and recurrent infections by ST11-KL64 carbapenem-resistantVirulence · 2026Article
- Article
- Comparative genomics of hypervirulent Klebsiella pneumoniae isolates from Brazil.Archives of microbiology · 2026Article
- Article
- Hypermucoviscosity inJournal of bacteriology · 2026Review
- Enhanced invasiveness promotes the dominance of a widely-distributed carbapenem-resistant virulence-plasmid-carrying Klebsiella pneumoniae sublineage.Nature communications · 2026Article
- Hidden burden of intestinal Klebsiella pneumoniae in Taiwan: insights into pathogenic potentials and genomic diversity.Gut pathogens · 2026Article
- Balanced Expression of the Diiron Oxygenase BioE Is Essential for Biotin Homeostasis in Elizabethkingia meningoseptica.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Fitness cost of ceftazidime-avibactam resistance acquisition in carbapenem-resistant hypervirulent Klebsiella pneumoniae.BMC microbiology · 2026Article
- Machine learning-based prediction of carbapenem-resistantFrontiers in pharmacology · 2026Article
- Genomic and functional characterization of ST11-KL64 hypervirulence-associated carbapenem-resistantFrontiers in microbiology · 2026Article
- Genomic Characterization of Antimicrobial Resistance and Virulence in ST11 Carbapenem-ResistantInfection and drug resistance · 2026Article
- Article
- Article
- How Klebsiella pneumoniae controls its virulence.PLoS pathogens · 2025Review
- Tracing the evolutionary dynamics of carbapenem-resistant Escherichia coli in recurrent and multi-site infections.Gut pathogens · 2025Article
- Nosocomial transmission, adaption and clinical outcomes of carbapenem-resistant hypervirulent Klebsiella pneumoniae.BMC microbiology · 2025Article
- Phenotypic and Genotypic Characteristics of Hypervirulent Klebsiella pneumoniae (hvKp): A Narrative Review.Current microbiology · 2025Review
- Rapid Identification and Typing of Carbapenem-Resistant Klebsiella pneumoniae Using MALDI-TOF MS and Machine Learning.Microbial biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The emergence of nosocomial infections caused by hypervirulent and carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.